

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

LIGAND PHARMACEUTICALS INC  
Form 8-K  
March 30, 2005

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

-----

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 24, 2005

LIGAND PHARMACEUTICALS INCORPORATED  
(Exact name of registrant as specified in its charter)

DELAWARE  
(State or other jurisdiction of incorporation)

000-20720  
(Commission File Number)

10275 SCIENCE CENTER DRIVE,  
SAN DIEGO, CALIFORNIA  
(Address of principal executive offices)

(858) 550-7500  
(Registrant's telephone number, including area code)

77-0160744  
(I.R.S. Employer Identification No.)

92121-1117  
(Zip Code)

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE  
OR STANDARD; TRANSFER OF LISTING

Ligand Pharmaceuticals Incorporated announced that it received a NASDAQ delisting notification letter and will request a hearing before NASDAQ panel regarding continued listing of its common stock.

A copy of the press release is attached as Exhibit 99.1 hereto and is hererby incorporated herein by reference.

ITEM 9.01 EXHIBITS

EXHIBIT NUMBER DESCRIPTION

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

-----  
99.1

-----  
Press Release of the Company dated March 30, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned.

LIGAND PHARMACEUTICALS INCORPORATED

Date : March 30, 2005

By: /S/WARNER BROADDUS

Name: Warner Broaddus

Title: Vice President, General Counsel & Secretary